Immune Therapy Drug Prolongs Survival in Advanced Lung Cancer Patients

A Bicycle That Has the Symptoms of MS
February 9, 2016
List of Hepatitis C Drugs – Direct Acting Antivirals
February 10, 2016
Show all

Immune Therapy Drug Prolongs Survival in Advanced Lung Cancer Patients

Patients with advanced non-small cell lung cancer resistant to chemotherapy may respond to an immune therapy drug commonly used to treat other cancers.

A newly published study involving patients with advanced non-small cell lung cancer resistant to chemotherapy has found a promising weapon in an immune therapy drug commonly used to treat other cancers.

The findings were published December 19 in The Lancet and presented at the 2015 annual conference of the European Society for Medical Oncology in Singapore.

The study, called KEYNOTE 010, compared pembrolizumab with the chemotherapy drug docetaxel in 1,034 patients with NSCLC whose tumors expressed the PD-L1 biomarker. PD-L1 is a protein expressed by many tumor types that can render the cancer invulnerable to immune attack. The study endpoints were overall survival (OS), progression-free survival (PFS), and safety.

Patients whose tumors expressed even low levels of PD-L1 benefited significantly from pembrolizumab. Patients with tumors that expressed the highest amounts of PD-L1 responded better and lived, on average, twice as long as patients treated with docetaxel alone (14.9 months versus 8.2 months), said senior author Roy S. Herbst, M.D., the Ensign Professor of Medicine and chief of medical oncology at Yale Cancer Center and Smilow Cancer Hospital at Yale-New Haven.

“I believe we should treat patients with the best available drugs as soon as possible. Now that we have learned which patients are most likely to benefit from the anti–PD-L1 strategy, we could begin moving this drug to the earlier setting stages,” Herbst said. “In this direction, I am eager to see the results of ongoing studies testing pembrolizumab in the first-line setting and as an adjuvant after surgery to hopefully reduce high rates of lung cancer recurrence.”

Read Full Article: Immune Therapy Drug Prolongs Survival in Advanced Lung Cancer Patients

Comments are closed.